Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, “Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 2017–2026.” Veterinary research has been used in regenerative and adult stem cell therapy and has gained significant traction over the last decade.
Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.
Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process.
|To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/15550|
The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.
In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then.
This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.
- VETSTEM BIOPHARMA
- Cell Therapy Sciences
- Regeneus Ltd.
- Aratana Therapeutics
- Medivet Biologics LLC
- Magellan Stem Cells
- ANIMAL CELL THERAPIES, INC
According to the Persistence Market Research report, the global canine stem cell therapy market is expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.
For Critical Insights On The Canine Stem Cell Therapy Market, Request For Customization Here @ https://www.persistencemarketresearch.com/request-customization/15550
Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market
Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.
A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.
However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.
Expensive Nature of Therapy to Obstruct Growth Trajectory
Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption.
The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians. A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs.
For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/15550
Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance.
The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.